WO2001013933A3 - Agents for the enhanced oxygen delivery in mammals - Google Patents

Agents for the enhanced oxygen delivery in mammals Download PDF

Info

Publication number
WO2001013933A3
WO2001013933A3 PCT/US2000/022583 US0022583W WO0113933A3 WO 2001013933 A3 WO2001013933 A3 WO 2001013933A3 US 0022583 W US0022583 W US 0022583W WO 0113933 A3 WO0113933 A3 WO 0113933A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammals
agents
oxygen delivery
enhanced oxygen
cytoplasm
Prior art date
Application number
PCT/US2000/022583
Other languages
French (fr)
Other versions
WO2001013933A2 (en
WO2001013933A9 (en
Inventor
Yves Claude Nicolau
Jean-Marie Lehn
Original Assignee
Gmp Companies Inc
Yves Claude Nicolau
Lehn Jean Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Companies Inc, Yves Claude Nicolau, Lehn Jean Marie filed Critical Gmp Companies Inc
Priority to AU69125/00A priority Critical patent/AU6912500A/en
Priority to JP2001518070A priority patent/JP2003507430A/en
Priority to EP00957519A priority patent/EP1223942A2/en
Publication of WO2001013933A2 publication Critical patent/WO2001013933A2/en
Publication of WO2001013933A3 publication Critical patent/WO2001013933A3/en
Publication of WO2001013933A9 publication Critical patent/WO2001013933A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention comprises compounds, compositions thereof, and methods capable of delivering a broad range of anionic molecules to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering a ligand for the allosteric site of hemoglobin to the cytoplasm of the blood cells.
PCT/US2000/022583 1999-08-25 2000-08-17 Agents for the enhanced oxygen delivery in mammals WO2001013933A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU69125/00A AU6912500A (en) 1999-08-25 2000-08-17 Enhanced oxygen delivery in mammals, methods and reagents related thereto
JP2001518070A JP2003507430A (en) 1999-08-25 2000-08-17 Drugs that enhance oxygen transport in mammals
EP00957519A EP1223942A2 (en) 1999-08-25 2000-08-17 Agents for the enhanced oxygen delivery in mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15057499P 1999-08-25 1999-08-25
US60/150,574 1999-08-25

Publications (3)

Publication Number Publication Date
WO2001013933A2 WO2001013933A2 (en) 2001-03-01
WO2001013933A3 true WO2001013933A3 (en) 2001-07-19
WO2001013933A9 WO2001013933A9 (en) 2002-09-12

Family

ID=22535137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022583 WO2001013933A2 (en) 1999-08-25 2000-08-17 Agents for the enhanced oxygen delivery in mammals

Country Status (4)

Country Link
EP (1) EP1223942A2 (en)
JP (1) JP2003507430A (en)
AU (1) AU6912500A (en)
WO (1) WO2001013933A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001279118A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
CA2377442A1 (en) * 2002-03-20 2003-09-20 Thomas Ichim Increasing tumor oxygen content by administration of stressed cells
EP1503768B1 (en) * 2002-04-29 2015-10-28 NormOxys, Inc. Inositol pyrophosphates, and use thereof
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
WO2007123126A1 (en) * 2006-04-17 2007-11-01 Juridical Foundation Osaka Industrial Promotion Organization Agent for improving decreased exercise tolerance in chronic heart failure
FR2944106B1 (en) * 2009-04-03 2012-09-28 Erytech Pharma METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
CN108464976A (en) 2009-06-22 2018-08-31 扩散药品有限公司 Diffusion promotes compound and its independent or application together with Thrombolytic Drugs
US8974822B2 (en) 2010-06-02 2015-03-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2014039660A1 (en) * 2012-09-06 2014-03-13 Biomet Biologics, Llc Methods for producing rejuvenated red blood cells
US10253295B2 (en) 2012-09-06 2019-04-09 Biomet Manufacturing, Llc Methods for producing rejuvenated red blood cells
US9066909B2 (en) 2012-09-06 2015-06-30 Biomet Biologics, Llc Methods for producing and using rejuvenated red blood cells
US9011408B2 (en) 2013-01-31 2015-04-21 Biomet Biologics, Llc Functionally-closed, sterile blood processing solution system and method
US9102918B2 (en) 2013-01-31 2015-08-11 Biomet Biologics, Llc Methods for rejuvenating red blood cells
US9103842B2 (en) 2013-01-31 2015-08-11 Biomet Biologics, Llc Methods for rejuvenating red blood cells
KR102489034B1 (en) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer
JP2018135329A (en) * 2018-02-19 2018-08-30 ディフュージョン・ファーマシューティカルズ・エルエルシー Bipolar trans carotenoid salts and uses thereof
EP3917535A1 (en) * 2019-01-30 2021-12-08 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in increasing tissular perfusion

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338916A1 (en) * 1988-04-20 1989-10-25 Pasteur Merieux Serums Et Vaccins Haemoglobin macromolecular complexes, method of preparation and their uses
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
EP0452055A1 (en) * 1990-04-11 1991-10-16 Hewlett-Packard Company Surfaces with reduced protein interactions
US5079337A (en) * 1986-07-02 1992-01-07 Pasteur Merieux Serums Et Vaccins S.A. Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses
JPH04300838A (en) * 1991-03-28 1992-10-23 Terumo Corp Artificial erythrocyte and its suspension
WO1992020335A1 (en) * 1991-05-20 1992-11-26 Center For Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5599974A (en) * 1994-09-19 1997-02-04 Center For Innovative Technology Aldehydic agents for allosteric modification of hemoglobin
US5612207A (en) * 1993-03-23 1997-03-18 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
WO1997042819A1 (en) * 1996-05-13 1997-11-20 Alberto Haces Cationic lipids for transfection of negatively charged or neutral molecules into living cells
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
WO1998039358A1 (en) * 1997-03-06 1998-09-11 Genta Incorporated Oligomeric cationic lipids
WO1998039359A1 (en) * 1997-03-06 1998-09-11 Genta Incorporated Dimeric cationic lipids on dicystine basis
US5872282A (en) * 1990-12-07 1999-02-16 Virginia Commonwealth University Allosteric modifiers of hemoglobin
US5927283A (en) * 1990-02-12 1999-07-27 Virginia Commonwealth University Allosteric modifiers of hemoglobin

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079337A (en) * 1986-07-02 1992-01-07 Pasteur Merieux Serums Et Vaccins S.A. Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses
US5110909A (en) * 1988-04-20 1992-05-05 Institut Merieux Macromolecular conjugates of hemoglobin, a procedure for their preparation and their uses
EP0338916A1 (en) * 1988-04-20 1989-10-25 Pasteur Merieux Serums Et Vaccins Haemoglobin macromolecular complexes, method of preparation and their uses
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5927283A (en) * 1990-02-12 1999-07-27 Virginia Commonwealth University Allosteric modifiers of hemoglobin
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
EP0452055A1 (en) * 1990-04-11 1991-10-16 Hewlett-Packard Company Surfaces with reduced protein interactions
US5872282A (en) * 1990-12-07 1999-02-16 Virginia Commonwealth University Allosteric modifiers of hemoglobin
JPH04300838A (en) * 1991-03-28 1992-10-23 Terumo Corp Artificial erythrocyte and its suspension
WO1992020335A1 (en) * 1991-05-20 1992-11-26 Center For Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5612207A (en) * 1993-03-23 1997-03-18 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
US5599974A (en) * 1994-09-19 1997-02-04 Center For Innovative Technology Aldehydic agents for allosteric modification of hemoglobin
WO1997042819A1 (en) * 1996-05-13 1997-11-20 Alberto Haces Cationic lipids for transfection of negatively charged or neutral molecules into living cells
WO1998039359A1 (en) * 1997-03-06 1998-09-11 Genta Incorporated Dimeric cationic lipids on dicystine basis
WO1998039358A1 (en) * 1997-03-06 1998-09-11 Genta Incorporated Oligomeric cationic lipids

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
A. N. CHUVILIN ET AL.: "Allosteric regulators of reversible hemoglobin oxygenation", BIOORG. KHIM., vol. 16, no. 9, 1990, pages 1157 - 1176, XP002156415 *
B. PITARD ET AL.: "Structural characteristics of supramolecular assemblies formed by guanidinium-cholesterol reagents for gene transfection", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 6, 1999, pages 2621 - 2626, XP000941540 *
C. NADOLNY ET AL.: "Specific Interactions of the Allosteric Effector 2,3-Bisphosphoglycerate with Human Hemoglobin - A Difference FTIR Study", BIOL. CHEM. HOPPE-SEYLER, vol. 374, no. 6, 1993, pages 403 - 407, XP000943782 *
D. L. CURRELL ET AL.: "Synthetic polyphosphonates, polyphosphates, and phosphonocarboxylates as allosteric effectors of hemoglobin", PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 51-52, no. 1-4, 1990, pages 35 - 38, XP000943807 *
E. ANTONINI ET AL.: "The Effect of Anions and Cations on the Oxygen Equilibrium of Human Hemoglobin", OXYGEN AFFINITY HEMOGLOBIN RED CELL ACID BASE STATUS, PROC. ALFRED BENZON SYMP., 4TH (25YHA4), 1972, pages 121 - 130, XP000944291 *
I. PAPASSOTIRIOU ET AL.: "Synthesized allosteric effectors of the hemoglobin molecule: A possible mechanism for improved erythrocyte oxygen release capability in hemoglobinopathy H disease", EXPERIMENTAL HEMATOLOGY, vol. 26, no. 10, 1998, pages 922 - 926, XP000943784 *
I. TABUSHI ET AL.: "Artificial Allosteric Molecules - Especially Focusing upon Allosteric O2 Binding Molecules of the Hemoglobin Type", MOL. STRUCT. ENERG., vol. 10, 1988, pages 195 - 218, XP000943789 *
J.-P- VIGNERON ET AL.: "Guanidinium-cholesterol cationic lipids: Efficient vectors for the transfection of eukaryotic cells", PROC. NATL. ACAD. SCI. USA, vol. 93, no. 18, 1996, pages 9682 - 9686, XP002030510 *
J.-P. VIGNERON: "Supramolecular Bioorganic Chemistry: Nucleic Acids Recognition and Synthetic Vectors for Gene Transfer", MOLECULES, vol. 4, 1999, pages 180 - 203, XP002156416 *
K. S. KILGORE ET AL.: "RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass", CIRCULATION, SUPPL., vol. 100, no. 19, 1999, pages 351 - 356, XP000943791 *
K. UCHIDA ET AL.: "Effect of an Allosteric Modifier of Hemoglobin, RSR-4, on Oxygen Affinity and Oxygen Saturation of Hemoglobin in Rabbits", JPN. J. PHYSIOL., vol. 48, no. 6, 1998, pages 439 - 444, XP000943772 *
N. OUDHIRI ET AL.: "Guanidinium-cholesterol cationic lipids: novl reagents for gene transfection and perspectives for gene therapy", BIOGENIC AMINES, vol. 14, no. 5, 1998, pages 537 - 552, XP000944064 *
N. OUDRHIRI ET AL.: "Gene transfer by guanidinium-cholesterol cationic lipids into airway epithelial cells in vitro and in vivo", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 5, 1997, pages 1651 - 1656, XP002035783 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 119 12 March 1993 (1993-03-12) *
W. J. FANTL ET AL.: "Specifically Carboxymethylated Hemoglobin as an Analogue of Carbamino Hemoglobin", J. BIOL. CHEM., vol. 262, no. 26, 1987, pages 12700 - 12713, XP000943847 *

Also Published As

Publication number Publication date
WO2001013933A2 (en) 2001-03-01
WO2001013933A9 (en) 2002-09-12
JP2003507430A (en) 2003-02-25
AU6912500A (en) 2001-03-19
EP1223942A2 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
WO2001013933A3 (en) Agents for the enhanced oxygen delivery in mammals
AU2274201A (en) Compounds and compositions for delivering active agents
AU7315301A (en) Compounds and compositions for delivering active agents
IL140930A0 (en) Compounds and compositions for delivering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA03007837A (en) Compositions for delivering bisphosphonates.
EP0993831A3 (en) Compounds and compositions for delivering active agents
IL195055A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2004043363A8 (en) Protein-stabilized liposomal formulations of pharmaceutical agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001091728A3 (en) Nanoemulsion formulations
EP0783299A4 (en) Compounds and compositions for delivering active agents
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MXPA03007857A (en) Compounds and compositions for delivering active agents.
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU7134898A (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
ATE456951T1 (en) ANTITUMORAL AGENTS AND METHOD FOR THE PRODUCTION THEREOF
WO2006041538A3 (en) A mixture for transdermal delivery of low and high molecular weight compounds
WO2002086074A3 (en) Compositions for delivery of compounds to cells and methods of use
WO2004002403A3 (en) Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU2001289762A1 (en) Pharmaceutical extemporary compositions
WO2003053457A8 (en) Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000957519

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000957519

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000957519

Country of ref document: EP